Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. 

However, even the slightest setback can prove detrimental to the existence of these companies. Failure to meet clinical endpoints, lack of funding or rejection from regulatory authorities are risks that these companies have to bear in pursuit of excellence. 

We delve into Ardelyx, Inc. (NASDAQ: ARDX) in our coverage today and see what's in store for the future!

Read more